Promising new combo tackles Hard-to-Treat prostate cancer

NCT ID NCT07082920

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Oct 01, 2025 · Last updated May 07, 2026 · Updated 28 times

Summary

This early-stage study tests a combination of two experimental drugs for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. One drug helps the immune system find and attack cancer cells, while the other delivers a toxic payload directly to them. The goal is to find the safest and most effective dose and see if the combination can shrink tumors or slow the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Royal Marsden Hospital (Sutton)
RECRUITING

Sutton, SM2 5PT, United Kingdom
The Christie Nhs Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States

Conditions

Explore the condition pages connected to this study.

PROSTATIC NEOPLASMS